TGA approval for CSL Behring lung therapy
28 February 2017 via Biotech Dispatch: The TGA has approved CSL Behring’s ZEMAIRA for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
AATD is a hereditary condition that can severely affect a patient’s lung function. The condition is marked by a low level or absence of Alpha-1 Proteinase Inhibitor (A1-PI), a natural protein that inhibits neutrophil elastase, thereby protecting the lungs from inflammation.
Severe deficiency of A1-PI is associated with a strong tendency for the development of emphysema and can significantly impact quality of life and life expectancy.
Read more in Biotech Dispatch.